Dr Helen Parry describes the findings of a new University of Birmingham-led study which has shown that a third of patients with the most common type of leukaemia fail to generate any measurable antibody response following two doses of COVID-19 vaccination. Furthermore, the research showed that in the two thirds of patients who do develop antibodies, levels are much lower than compared to healthy people and also have a profoundly reduced ability to ‘neutralise’ the globally dominant Delta variant.

Find out more at: https://www.birmingham.ac.uk/news/latest/2021/10/covid-vaccination-leukaemia-antibody-response.aspx